CEO Total Pay
$19.8M
FY2021 Summary Compensation
SRNE
FY2021 data Public-data reference. official source
Sorrento Therapeutics, Inc.
Data updated July 2026
Open-data reference.
Chemicals & Pharmaceuticals · DE · FY2021
CEO-to-Worker Pay Ratio
152:1
High (Scale: 0–1000:1)
CEO Pay
$19.8M
Median Worker
$130,192
A component-level pay breakdown (salary, bonus, equity, perks, pension) is not reported in Sorrento Therapeutics, Inc.'s structured SEC pay-ratio disclosure. Only the CEO-to-median-worker ratio is required under Dodd-Frank §953(b); see our methodology for what each filing does and doesn't disclose.
Sorrento Therapeutics, Inc., a chemicals & pharmaceuticals company, reported a CEO-to-worker pay ratio of 152:1 in FY2021. The CEO received total compensation of $19.8M, while the median employee earned $130,192 annually. This is above the Chemicals & Pharmaceuticals industry median of 44:1 across 165 companies. Data sourced from SEC EDGAR proxy (DEF 14A) filings.
CEO Compensation Breakdown, FY2021
A component-level pay breakdown is not reported in Sorrento Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
152:1
Industry Median Ratio
44:1
Industry Median CEO Pay
$8.3M
This CEO's Pay
$19.8M
Companies in Industry
165
vs. Industry Median
Above
Understanding This Pay Ratio
Sorrento Therapeutics, Inc.'s CEO-to-worker pay ratio of 152:1 means that the CEO earned 152 times more than the company's median employee in FY2021.
The median employee at Sorrento Therapeutics, Inc. earned $130,192 annually. At that wage, it would take a median employee approximately 152 years to earn what the CEO earned in a single year.
Why cross-company pay-ratio comparisons need caution
SEC rules let each company choose its own methodology for identifying the "median employee" (measurement date, statistical sampling, whether part-time pay is annualized, and a de minimis exemption for up to 5% of non-U.S. employees), so a higher ratio doesn't automatically mean less-fair pay practices, it can also reflect workforce mix (a large offshore, outsourced, or part-time-heavy workforce lowers the reported median and raises the ratio for reasons unrelated to CEO compensation itself).
Pay Ratio
152:1
Elevated vs peers
What This 2021 Filing Tells Us About Sorrento Therapeutics, Inc.
According to the 2021 DEF 14A proxy statement filed with the SEC, Sorrento Therapeutics, Inc. (SRNE, CIK 850261) reported the CEO's total compensation at $19.8M. The proxy statement's structured pay-ratio disclosure reports this total but does not break it down by salary, bonus, equity, or other components. The median employee at the firm, the reference point mandated by Section 953(b) of the Dodd-Frank Act, earned $130,192 over the same fiscal year, producing the headline CEO-to-worker pay ratio of 152:1 that this page tracks.
Sorrento Therapeutics, Inc. operates in the Chemicals & Pharmaceuticals sector and is headquartered in DE. Across the Chemicals & Pharmaceuticals industry (SIC 28), 165 SEC-reporting companies disclosed pay ratios in FY2025, with a median of 44:1 and an average of 75:1. Median industry CEO pay was $8.3M, so Sorrento Therapeutics, Inc.'s $19.8M sits above that typical figure.
This proxy was filed on 2022-11-01; all figures on this page come directly from that public filing and can be verified against the DEF 14A on the SEC EDGAR system.
What these SEC numbers do and do not include
Total compensation reported under Item 402 of Regulation S-K reflects grant-date fair value for equity awards, not realized pay, so a CEO may eventually cash in more, or less, depending on stock performance and vesting. The pay ratio itself is calculated against a single median employee chosen under rules that allow statistical sampling, and companies may update methodology year to year.
Key Data, FY2021
- CEO
- Not disclosed
- Total Compensation
- $19.8M
- Median Employee Pay
- $130,192
- Pay Ratio
- 152:1
- Filing Date
- 2022-11-01
Company Info
- Ticker
- SRNE
- CIK
- 850261
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- DE
Data Source: This data is sourced from SEC EDGAR proxy statement (DEF 14A) filings. PlainCEOPay provides this publicly available information for informational purposes only. Not investment or financial advice. Verify with official SEC filings at sec.gov.
Frequently Asked Questions
What is the CEO pay ratio at Sorrento Therapeutics, Inc.? ▼
Sorrento Therapeutics, Inc.'s CEO-to-worker pay ratio is 152:1. The CEO earned $19.8M in FY2021, while the median employee earned $130,192.
How much does Sorrento Therapeutics, Inc.'s CEO earn? ▼
The CEO of Sorrento Therapeutics, Inc. (SRNE) earned total compensation of $19.8M in fiscal year 2021, according to SEC proxy filings.
How does Sorrento Therapeutics, Inc.'s pay ratio compare to its industry? ▼
Sorrento Therapeutics, Inc.'s pay ratio of 152:1 is above the Chemicals & Pharmaceuticals industry median of 44:1. The industry has 165 companies reporting pay ratios.
Where does Sorrento Therapeutics, Inc.'s CEO pay data come from? ▼
All executive compensation data is sourced from SEC EDGAR DEF 14A proxy statement filings. Companies are required by the Dodd-Frank Act to disclose CEO-to-median-worker pay ratios annually. PlainCEOPay aggregates this publicly available data for easy comparison.
What is included in the CEO's total compensation? ▼
PlainCEOPay reports the CEO total-compensation figure disclosed with the company's pay-ratio filing. The current dataset does not extract its underlying Summary Compensation Table line items, so this page does not provide a salary, bonus, equity, or other-component breakdown.
How long would it take a median Sorrento Therapeutics, Inc. employee to earn the CEO's pay? ▼
At a median salary of $130,192, it would take the typical Sorrento Therapeutics, Inc. employee approximately 152 years to earn what the CEO earned in a single year ($19.8M in FY2021).
Read our methodology - how this data is sourced, computed, and verified.
Related
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainCEOPay
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed July 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
Every figure on PlainCEOPay is rendered directly from SEC EDGAR executive compensation filings, no number is typed in by an editor. Executive pay figures are computed directly from SEC EDGAR filings, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.